Skip to Content


Active Substance: colestilan
Common Name: colestilan
ATC Code: V03AE
Marketing Authorisation Holder: Mitsubishi Pharma Europe Ltd
Active Substance: colestilan
Status: Withdrawn
Authorisation Date: 2013-01-21
Therapeutic Area: Hyperphosphatemia
Pharmacotherapeutic Group: Drugs for treatment of hyperkalaemia and hyperphosphataemia

Therapeutic Indication

Treatment of hyperphosphataemia in adult patients with chronic kidney disease stage 5 receiving haemodialysis or peritoneal dialysis.

The marketing authorisation for BindRen has been withdrawn at the request of the marketing authorisation holder.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.